Therefore, the future holds promise, especially with the development of genetic therapies and further advanced CFTR modulators that restoration of CFTR activity can aid in attenuating respiratory infections in CF, but a majority of the adult pwCF will remain infected with different multidrug resistant airway bacteria and will need additional therapies they can tolerate to improve their quality and quantity of life. This evidence concerns the gene CFTR and cystic fibrosis.